HGH Fragment 176-191 FR
hGH C-terminal fragment
Peptide matching the C-terminal region of human growth hormone, studied for lipolytic activity; most published work uses the analogue AOD9604.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- hGH C-terminal fragment
- Category
- Fat Metabolism & Lipotropics
- Type
- Single compound
- Abbreviation
- FR
- Development and regulatory status
- Not approved; research compound with limited public data
What researchers study
HGH Fragment 176-191 is a peptide corresponding to the C-terminal region of human growth hormone, studied for lipolytic activity. Most published work uses the modified analogue AOD9604 rather than this fragment.
Research areas
- Lipolysis in adipocytes and animal models
- Growth hormone C-terminal domain structure-function
- Fat oxidation and adipose-tissue biology
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- rodent
Retrieved studies mainly concern the analogue AOD9604, which raised fat oxidation and plasma glycerol in obese mice
- phase 2 trial
A phase 2b trial of the analogue AOD9604 found no dose significantly different from placebo at its primary endpoint
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- AOD9604modified analogue of the same C-terminal growth hormone region
- TesamorelinGHRH analogue acting on the growth hormone axis
